Experimental anti-coronavirus drug remdesivir fails in human trial

Gilead Sciences, the company behind the medicine, disputed how the WHO had characterized the findings, saying the result data showed a 'potential benefit'.

Published: 24th April 2020 11:22 AM  |   Last Updated: 24th April 2020 11:23 AM   |  A+A-

A vial of the investigational drug remdesivir is visually inspected at a Gilead Sciences manufacturing site in US

A vial of the investigational drug remdesivir is visually inspected at a Gilead Sciences manufacturing site in US. (Photo| AP)


NEW YORK: The experimental coronavirus treatment remdesivir has failed in its first randomized clinical trial, inadvertently released results showed on Thursday, dampening expectations for the closely watched drug.

A draft summary went online briefly on the website of the World Health Organization (WHO) and was first reported by the Financial Times and Stat, which posted a screenshot. But Gilead Sciences, the company behind the medicine, disputed how the now-deleted post had characterized the findings, saying the data showed a "potential benefit."

ALSO READ| France plans trials to check whether nicotine could prevent coronavirus infection

The summary said the Chinese trial involved 237 patients, with 158 on the drug and 79 in a control group. Remdesivir was stopped early in 18 patients because of side effects. The authors said that remdesivir was "not associated with a difference in time to clinical improvement" compared to the control.

After a month, 13.9 percent of the patients on remdesivir had died compared to 12.8 percent of those in the control group. The difference is not statistically significant. The WHO told the Financial Times that the draft is undergoing peer review and was published early in error.

Trials continue

A spokesman for Gilead told AFP: "We believe the post included inappropriate characterizations of the study," saying it was terminated early due to low enrollment and was therefore not statistically meaningful. As such, the study results are inconclusive, though trends in the data suggest a potential benefit for remdesivir, particularly among patients treated early in disease."

The study does not represent the final word on the matter, and there are several large-scale trials in advanced stages that should soon provide a clearer picture.

ALSO READ| COVID-19 vaccine: Human trials begin in UK, scientists give 80 percent success rate

Remdesivir, which is administered intravenously, was among the first drugs suggested as a treatment for the novel coronavirus and as such has great hopes riding on it. Stephen Evans, a professor of pharmacoepidemiology at the London School of Hygiene & Tropical Medicine, who was not involved in the research, said "the trial was too small in numbers recruited" to detect either benefit or risk.

But he added: "If the drug only works well when given very early after infection, it may be much less useful in practice."

Last week, Stat reported it had shown significant efficacy at a Chicago hospital where patients who are part of one of the major trials are being treated. The US National Institutes for Health also reported it had proven effective in a small experiment on monkeys.

Remdesivir, which previously failed in trials against Ebola, belongs to a class of drugs that act on the virus directly -- as opposed to controlling the abnormal and often lethal autoimmune response it causes. It mimics one of the four building blocks of RNA and DNA and gets absorbed into the virus's genome, which in turn stops the pathogen from replicating.

The antimalarial drugs hydroxychloroquine and chloroquine are also being widely used on COVID-19 on a so-called "compassionate basis" pending results from large trials, with early studies decidedly mixed.

ALSO READ| COVID-19 killed by sunlight, warmer temperatures, humidity: White House

Other therapies that are being studied include collecting antibodies from COVID-19 survivors and injecting them in patients, or harvesting antibodies from genetically-engineered mice that were deliberately infected.


Disclaimer : We respect your thoughts and views! But we need to be judicious while moderating your comments. All the comments will be moderated by the editorial. Abstain from posting comments that are obscene, defamatory or inflammatory, and do not indulge in personal attacks. Try to avoid outside hyperlinks inside the comment. Help us delete comments that do not follow these guidelines.

The views expressed in comments published on are those of the comment writers alone. They do not represent the views or opinions of or its staff, nor do they represent the views or opinions of The New Indian Express Group, or any entity of, or affiliated with, The New Indian Express Group. reserves the right to take any or all comments down at any time.

  • Sadasivan

    Interferon Alpha 2 B has been used for 40 years for treating Corona Viruses.
    1 year ago reply
flipboard facebook twitter whatsapp